openPR Logo
Press release

Hyperlipidemia Market Opportunities And Strategies 2024-2033 - Growth Analysis, Outlook, Overview

05-17-2024 07:29 AM CET | Health & Medicine

Press release from: The Business research company

Hyperlipidemia Market Size

Hyperlipidemia Market Size

The hyperlipidemia market size has grown steadily in recent years. It will grow from $19.41 billion in 2023 to $20.24 billion in 2024 at a compound annual growth rate (CAGR) of 4.2%. The growth in the historic period can be attributed to growing demand for effective treatments, geographic expansion, growing public awareness of hyperlipidemia, tobacco use.

The hyperlipidemia market size is expected to see steady growth in the next few years. It will grow to $23.25 billion in 2028 at a compound annual growth rate (CAGR) of 3.5%. The growth in the forecast period can be attributed to growing demand for hyperlipidemia drugs, global health initiatives, aging population, preventive care and early intervention. Major trends in the forecast period include novel therapies, digital health technologies in hyperlipidemia management, biomarkers in hyperlipidemia diagnosis and treatment, research & development activities of pharmaceuticals treatments.

Market Overview -
Hyperlipidemia is a medical condition characterized by abnormally high levels of lipids (fats) in the blood, including cholesterol and triglycerides. It is a common metabolic disorder and a significant risk factor for cardiovascular diseases.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=12873&type=smp

Elevating Demand In The Hyperlipidemia Market Driven By Rising Incidences Of Heart Disease
Increasing incidences of chronic disorders such as heart disease are expected to propel the growth of the hyperlipidemia market going forward. Heart diseases refer to diseases that affect the heart and its functioning. Hyperlipidemia treatment helps people suffering from heart disease by lowering the risk of heart attacks, preventing strokes, improving endothelial function and reducing the need for invasive interventions. For instance, in March 2022, according to a report published by The Office for National Statistics, a UK-based government department, the number of deaths due to heart attacks increased from 19,440 in 2020 to 20,061 in 2021. Therefore, increasing incidences of chronic disorders such as heart disease drive the growth of the hyperlipidemia market.

Competitive Landscape -
Major players in the hyperlipidemia market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Menarini Group, Ipsen S.A., Dr. Reddy's Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Cipla Inc., Endo International PLC, Aspen Pharmacare Holdings Limited, Zydus Lifesciences Ltd., LEO Pharma A/S.

Innovative Products Drive Competitive Advantage For Leading Companies In The Hyperlipidemia Market
Major companies operating in the hyperlipidemia market are focused on developing innovative products, such as advanced lipid-lowering therapies, to sustain their position in the market. For example, in December 2021, Novartis, a US-based pharmaceutical company, launched a new hyperlipidemia drug called Leqvio (inclisiran), approved by the Food and Drug Administration, a US-based government agency. This is the first-in-class siRNA (small interfering RNA) drug that is used to lower cholesterol as an adjunct treatment to diet and statin therapy for adults with clinical atherosclerotic cardiovascular disease (ASCVD) and heterozygous familial hypercholesterolemia (HeFH) who require additional lowering of low-density lipoprotein cholesterol (LDL-C).

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/hyperlipidemia-global-market-report

Key Segments -

The hyperlipidemia market covered in this report is segmented -
1) By Type: Familial; Acquired
2) By Treatment: Statins; PCSK9 Inhibitors; Bile Acid Sequestrants; Cholesterol Absorption Inhibitors; Fibric Acid Derivatives; Combination; Other Treatment
3) By Route of Administration: Oral; Parenteral
4) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

"Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model "

"Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps"

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hyperlipidemia Market Opportunities And Strategies 2024-2033 - Growth Analysis, Outlook, Overview here

News-ID: 3500495 • Views:

More Releases from The Business research company

Hydrofluoric Acid Market to Hit $1.87 Billion by 2028 with a CAGR of 5.7%, Driven by Industrial Demand
Hydrofluoric Acid Market to Hit $1.87 Billion by 2028 with a CAGR of 5.7%, Drive …
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033. Hydrofluoric Acid Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance. The Market Size Is Expected To Reach $1.87 billion In 2028 At
Green Building Materials Market to Reach $490.8 Billion by 2028 at 9.7% CAGR, Driven by Eco-Friendly Solutions and Urbanization
Green Building Materials Market to Reach $490.8 Billion by 2028 at 9.7% CAGR, Dr …
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033. Green Building Materials Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance. The Market Size Is Expected To Reach $490.8 billion In 2028
Feldspar Market to Hit $8.46 Billion by 2028 at 10.9% CAGR, Driven by Automotive Demand and Construction Boom
Feldspar Market to Hit $8.46 Billion by 2028 at 10.9% CAGR, Driven by Automotive …
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033. Feldspar Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance. The Market Size Is Expected To Reach $8.46 billion In 2028 At A
Electric Ships Market to Reach $13.63 Billion by 2028 at 11.0% CAGR, Driven by H …
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033. Electric Ships Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance. The Market Size Is Expected To Reach $13.63 billion In 2028 At

All 5 Releases


More Releases for Hyperlipidemia

Hyperlipidemia Drug Market Trends, Research Report, Growth, Opportunities, Forec …
The global hyperlipidemia drug market is anticipated to grow at a significant CAGR during the forecast period. The major factor for the growth of the global hyperlipidemia market during the forecast period is the rapidly growing consumption of dairy products along with the sedentary lifestyle is fueling the market. Statins are the first line of treatment for hyperlipidemia. The expiration of patents of branded drugs will lead to the genericization
Hyperlipidemia Drugs Market Size - Forecasts to 2026
As per the research conducted by GME, the Hyperlipidemia Drugs Market is estimated to be valued at USD 21.84 Billion in 2021 and is projected to reach USD 24.71 Billion by 2026 at a CAGR of 2.5%. increasing unusual cholesterol levels, upsurge in high-density lipoprotein (HDL) and low-density lipoprotein (LDL) level cost-effective innovations, growing public awareness of nutraceuticals, increasing innovations in biotechnology, government initiatives, and increasing research and developments activities
Global Hyperlipidemia Drug Market Size, Comprehensive Analysis & Forecast to 202 …
The global hyperlipidemia drug market is estimated to witness significant growth during the forecast period. The demand for a statin to manage cholesterol is driving the market growth across the globe. This drug supports lowering cholesterol, hence reduce the chances of cardiovascular diseases, stroke, and diabetes. Statins are used to manage the plaque on blood vessels and reduce the risk of blood clots. There are various statins options are available
Hyperlipidemia Drugs Market - Operational challenges 2028 | Dr. Reddy's Laborato …
Global Hyperlipidemia Drugs Market: Overview Hyperlipidemia is a technical term for abnormal amounts of fats (lipids) in the blood. The two noteworthy sorts of lipids found in the blood are triglycerides and cholesterol. Triglycerides are made when your body stores the additional calories it doesn't require for producing energy. They additionally come specifically from a man's eating routine in nourishments, for example, red meat and entire fat dairy. An eating regimen
Hyperlipidemia Therapeutics Pipeline Review 2018 - Clinical Trials, Results, Des …
Hyperlipidemia refers to elevated amount of lipids and cholesterol in the bloodstream. The two major types of lipid abnormalities are characterized by either high blood levels of triglycerides (known as hypertriglyceridemia) or high blood cholesterol levels (known as hypercholesterolemia). Hyperlipidemia is often associated with increased risk of coronary heart disease and strokes. The study analyzed that hyperlipidemia therapeutics pipeline comprises 53 drug candidates in different stages of development. Explore report sample
Hyperlipidemia Prescription Drugs Market To Witness Exponential Growth By 2019
Hyperlipidemia refers to abnormal elevation of lipids and/or lipoprotein levels. Risk factors associated with such condition include stroke, peripheral vascular disease, atherosclerosis, diabetes, obesity, hypertension and other cardiovascular diseases. Drugs which are used to treat hyperlipidemia act by either accelerating the elimination of lipoproteins from the body or decrease production of lipoproteins. These medications not only lower the unwanted cholesterol levels but also prove to be vital for lowering the